Last reviewed · How we verify
Budecort Aqua
Budecort Aqua is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.
Budecort Aqua is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue. Used for Allergic rhinitis, Asthma (maintenance therapy).
At a glance
| Generic name | Budecort Aqua |
|---|---|
| Sponsor | Eurofarma Laboratorios S.A. |
| Drug class | Inhaled corticosteroid (ICS) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Budesonide, the active ingredient, is a selective glucocorticoid receptor agonist that suppresses inflammatory cytokine production and immune cell recruitment in the airways. When delivered as an aqueous nasal or inhaled spray formulation, it provides topical anti-inflammatory effects with minimal systemic absorption, reducing airway edema, mucus production, and bronchial hyperresponsiveness.
Approved indications
- Allergic rhinitis
- Asthma (maintenance therapy)
Common side effects
- Headache
- Nasal irritation
- Epistaxis
- Throat irritation
- Candidiasis (oral/pharyngeal)
Key clinical trials
- Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray (PHASE3)
- Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis (PHASE3)
- Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA) (PHASE3)
- Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels (PHASE3)
- Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer (PHASE2)
- Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis (PHASE3)
- Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis (PHASE2)
- Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budecort Aqua CI brief — competitive landscape report
- Budecort Aqua updates RSS · CI watch RSS
- Eurofarma Laboratorios S.A. portfolio CI